Harry Werner Kirsch

Chief Financial Officer at Novartis AG

Harry Werner Kirsch

Harry Werner Kirsch

Chief Financial Officer at Novartis AG

Overview
Career Highlights

Novartis AG
Novartis Venture Fund

RelSci Relationships

995

Number of Boards

7

Birthday

1965

Age

55

Relationships
RelSci Relationships are individuals Harry Werner Kirsch likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Former Chief Operating Officer at Novartis Corporation

Relationship likelihood: Strong

Head of the Novartis Vaccines & Diagnostics Division at Novartis Corporation

Relationship likelihood: Strong

Group General Counsel of Novartis at Novartis AG

Relationship likelihood: Strong

President at Novartis Institutes for BioMedical Research, Inc.

Relationship likelihood: Strong

Division Head, Alcon at Novartis AG

Relationship likelihood: Strong

Managing Director at Novartis Venture Fund

Relationship likelihood: Strong

Founder at Arrakis Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Former Group General Counsel at Novartis AG

Relationship likelihood: Strong

Paths to Harry Werner Kirsch
Potential Connections via
Relationship Science
You
Harry Werner Kirsch
Chief Financial Officer at Novartis AG
Education
Industrial Engineering & Economics
Career History
Chief Financial Officer
2003 - Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Financial Officer
Current

Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.

Vice Chairman
Current

Novartis Pharma KK develops, imports, produces and sells pharmaceutical products. The company was founded on April 1, 1997 and is headquartered in Tokyo, Japan.

Boards & Committees
Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Harry Werner Kirsch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Harry Werner Kirsch's profile does not indicate a business or promotional relationship of any kind between RelSci and Harry Werner Kirsch.